1. Home
  2. KMDA vs CTNM Comparison

KMDA vs CTNM Comparison

Compare KMDA & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kamada Ltd.

KMDA

Kamada Ltd.

SELL

Current Price

$8.15

Market Cap

460.3M

Sector

Health Care

ML Signal

SELL

Logo Contineum Therapeutics Inc.

CTNM

Contineum Therapeutics Inc.

SELL

Current Price

$9.51

Market Cap

550.7M

Sector

N/A

ML Signal

SELL

Company Overview

Basic Information
Metric
KMDA
CTNM
Founded
1990
2009
Country
Israel
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
460.3M
550.7M
IPO Year
2013
2024

Fundamental Metrics

Financial Performance
Metric
KMDA
CTNM
Price
$8.15
$9.51
Analyst Decision
Strong Buy
Buy
Analyst Count
3
8
Target Price
$13.75
★ $21.43
AVG Volume (30 Days)
103.5K
★ 506.3K
Earning Date
11-09-2026
11-03-2026
Dividend Yield
★ 6.86%
N/A
EPS Growth
N/A
★ 0.46
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$12.75
N/A
Revenue Next Year
$13.63
N/A
P/E Ratio
$24.59
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$6.60
$6.73
52 Week High
$9.35
$17.79

Technical Indicators

Market Signals
Indicator
KMDA
CTNM
Relative Strength Index (RSI) 56.89 46.04
Support Level $7.99 $8.59
Resistance Level $8.62 $13.72
Average True Range (ATR) 0.25 0.74
MACD 0.09 0.19
Stochastic Oscillator 88.61 41.47

Price Performance

Historical Comparison
KMDA
CTNM

About KMDA Kamada Ltd.

Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.

About CTNM Contineum Therapeutics Inc.

Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.

Share on Social Networks: